Nakamori Shoji, Endo Wakio, Ozato Hiroki, Shibata Takashi, Takeda Yutaka, Tohno Ken, Hasuike Yasunori, Masutani Seizo, Morimoto Takashi, Doki Yuichirou, Mori Masaki, Monden Morito
Pancreatic Cancer Study Group, Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University.
Gan To Kagaku Ryoho. 2011 May;38(5):789-92.
Our objective was to evaluate the efficacy and toxicity of the pre-administration of UFT (uracil/tegafur: prodrug of 5-FU) and GEM combination therapy for unresectable/recurrent pancreatic cancer in the outpatient setting. UFT (250mg/m(2)/day) was orally administered from day 1 through day 6 and from day 8 through 13, and GEM (800mg/m(2), div/30 min) was administered on day 7 and 14, with a one-week rest every 3 weeks based on results of the previous phase I study. Thirty-six pts (24 male, 12 female) were enrolled (median age, 63.8 yrs). There were 8 partial responses (25%). Eighteen pts (56%) had stable disease, and 6 pts (19%) had a progression. The median survival time was 7. 0 months( range 1.5 -66). Grade 3 toxicities were leucopenia (17%), thrombocytopenia (3%), nausea (3%), and liver dysfunctions(3%). There were no Grade 4 toxicities. Pre-administered UFT plus GM is a promising treatment for unresectable/recurrent pancreatic cancer in the outpatient setting.
我们的目的是评估在门诊环境中，术前给予优福定（尿嘧啶/替加氟：5-氟尿嘧啶的前体药物）和吉西他滨联合治疗不可切除/复发性胰腺癌的疗效和毒性。优福定（250mg/m²/天）于第1天至第6天以及第8天至第13天口服给药，吉西他滨（800mg/m²，分30分钟滴注）于第7天和第14天给药，根据之前I期研究的结果，每3周休息1周。36例患者（24例男性，12例女性）入组（中位年龄63.8岁）。有8例部分缓解（25%）。18例患者（56%）病情稳定，6例患者（19%）病情进展。中位生存时间为7.0个月（范围1.5 - 66个月）。3级毒性反应包括白细胞减少（17%）、血小板减少（3%）、恶心（3%）和肝功能障碍（3%）。无4级毒性反应。术前给予优福定加吉西他滨是门诊环境中治疗不可切除/复发性胰腺癌的一种有前景的治疗方法。
